Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors

BackgroundTo determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors.Patients and methodsPatients had advanced, refractory mismatch repair-proficient colorectal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal for immunotherapy of cancer 2020-10, Vol.8 (2), p.e001006
Hauptverfasser:	Razak, Albiruni RA, Cleary, James M, Moreno, Victor, Boyer, Michael, Calvo Aller, Emiliano, Edenfield, William, Tie, Jeanne, Harvey, R Donald, Rutten, Annemie, Shah, Manish A, Olszanski, Anthony J, Jäger, Dirk, Lakhani, Nehal, Ryan, David P, Rasmussen, Erik, Juan, Gloria, Wong, Hansen, Soman, Neelesh, Smit, Marie-Anne Damiette, Nagorsen, Dirk, Papadopoulos, Kyriakos P
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Apoptosis Biomarkers Biopsy Cancer clinical trials as topic Clinical/Translational Cancer Immunotherapy Drug dosages drug therapy, combination Enrollments gastrointestinal neoplasms Immunotherapy Ligands Lung cancer lung neoplasms Lymphocytes Monoclonal antibodies Pancreatic cancer Pharmacokinetics Targeted cancer therapy Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BackgroundTo determine the safety and efficacy of the anti-colony-stimulating factor 1 receptor (anti-CSF1R) monoclonal antibody AMG 820 in combination with pembrolizumab in patients with select solid tumors.Patients and methodsPatients had advanced, refractory mismatch repair-proficient colorectal cancer, pancreatic cancer, or non-small cell lung cancer (NSCLC) with low (
ISSN:	2051-1426 2051-1426
DOI:	10.1136/jitc-2020-001006